Stock Events

Stock Events

Abivax 

€75.65
146
-€5.55-6.83% 15:38 Today

Statistics

Day High
75.65
Day Low
75.15
52W High
136.9
52W Low
62.35
Volume
3
Avg. Volume
447
Mkt Cap
6.62B
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

Dec 14Expected
Q1 2026
Q2 2026
Next
-1.46
-1.18
-0.89
-0.61
Expected EPS
-0.8217276250262993
Actual EPS
N/A

Financials

-Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
0Revenue
-336.1MNet Income

Analyst Ratings

$117.27Average Price Target
The highest estimate is ⁦141.90⁩.
From 11 ratings within the last 6 months. This is not an investment recommendation.
Buy
82%
Hold
18%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow ABVX.VI. It's not an investment recommendation.
TotalEnergies
26
TTE.PA
Air Liquide
26
AI.PA
NVIDIA
20
NVDA
Engie
19
ENGI.PA

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Gilead Sciences
GILD
Mkt Cap211.7B
Gilead Sciences is a biopharmaceutical company that competes with Abivax in the development of antiviral drugs, including treatments for HIV, which is a focus area for Abivax.
Vertex Pharmaceuticals
VRTX
Mkt Cap141.65B
Vertex Pharmaceuticals is involved in creating antiviral treatments and therapies for infectious diseases, competing directly with Abivax's efforts in HIV and other viral infections.
Merck
MRK
Mkt Cap368.89B
Merck & Co., Inc. is a global healthcare company that develops antiviral drugs, including therapies for HIV/AIDS, positioning it as a competitor to Abivax.
GSK
GSK
Mkt Cap99.19B
GlaxoSmithKline plc focuses on developing and marketing vaccines and medications for HIV, directly competing with Abivax's research and development in HIV treatments.
Johnson & Johnson
JNJ
Mkt Cap657.68B
Johnson & Johnson, through its pharmaceutical division Janssen, works on developing treatments for infectious diseases, including HIV, making it a competitor to Abivax.
Abbvie
ABBV
Mkt Cap521.11B
AbbVie Inc. competes in the area of antiviral research, with a focus on therapies for HIV, hepatitis, and other viral infections, areas that Abivax is also targeting.
Pfizer
PFE
Mkt Cap173.95B
Pfizer Inc. is involved in the discovery, development, and manufacture of healthcare products, including antiviral drugs, competing with Abivax in the infectious disease space.
Bristol-Myers Squibb
BMY
Mkt Cap127.71B
Bristol Myers Squibb is engaged in the discovery and development of prescription medicines for various diseases, including HIV/AIDS, making it a direct competitor to Abivax.
Regeneron Pharmaceuticals
REGN
Mkt Cap95.99B
Regeneron Pharmaceuticals, Inc. is known for its work in biotechnology and the development of medicines for infectious diseases, competing with Abivax in the biopharmaceutical field.
Novartis
NVS
Mkt Cap303.67B
Novartis AG is a global healthcare company that researches and develops treatments for a wide range of diseases, including viral infections, competing with Abivax in the pharmaceutical and healthcare market.

About

Abivax SA is a France-based clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. The company is evaluating its drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of adults with moderately to severely active ulcerative colitis. Its initial focus is on inflammatory bowel diseases, chronic conditions involving inflammation of the gastrointestinal tract, of which the two common forms are UC and CD. The Group operates in a single operating segment: R&D of pharmaceutical products in order to market them in the future.
Show More
CEO
Marc de Garidel
Employees
69
Country
France
ISIN
FR0012333284
WKN
000A14UQC

Listings

F
DE
2X10.F
STU
DE
2X10.STU
XETRA
DE
2X1.XETRA
STU
DE
2X1.STU

0 Comments

Share your thoughts

FAQs

What is Abivax stock price today?▼
The current price of ABVX.VI is €75.65 EUR — it has decreased by -6.83% in the past 24 hours. Watch Abivax stock price performance more closely on the chart.
What is Abivax stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on Vienna Exchange exchange Abivax stocks are traded under the ticker ABVX.VI.
What is Abivax market cap?▼
Today Abivax has the market capitalization of 6.62B
When is the next Abivax earnings date?▼
Abivax is going to release the next earnings report on December 14, 2026.
What were Abivax earnings last quarter?▼
ABVX.VI earnings for the last quarter are -1.46 EUR per share, whereas the estimation was -0.8 EUR resulting in a -83.47% surprise. The estimated earnings for the next quarter are N/A EUR per share.
What is Abivax revenue for the last year?▼
Abivax revenue for the last year amounts to 0 EUR.
What is Abivax net income for the last year?▼
ABVX.VI net income for the last year is -336.1M EUR.
How many employees does Abivax have?▼
As of November 6, 2026, the company has 69 employees.
In which sector is Abivax located?▼
Abivax operates in the Health & Wellness sector.
When did Abivax complete a stock split?▼
Abivax has not had any recent stock splits.
Where is Abivax headquartered?▼
Abivax is headquartered in Paris, France.